CFPC works on educational program covering newly approved Mifegymiso

July 31, 2015

(July 31, 2015, Mississauga, ON) Health Canada has approved Mifegymiso, a medical abortion drug containing mifepristone, used to terminate early stage pregnancies. The drug will be available through a physician prescription only.

The College of Family Physicians of Canada (CFPC) has been working collaboratively with the Society of Obstetricians and Gynaecologists of Canada (SOGC) to develop educational initiatives to inform and support family physicians who prescribe this drug as part of their care for their female patients.

The CFPC will strive to inform and educate its members who require guidance to support them in light of this new approval. Additional information and resources will be shared as available.

The College of Family Physicians of Canada (CFPC) represents more than 34,000 members across the country. It is the professional organization responsible for establishing standards for the training, certification and lifelong education of family physicians. The College provides quality services and programs, supports family medicine teaching and research, and advocates on behalf of family physicians and the specialty of family medicine. The CFPC accredits postgraduate family medicine training in Canada’s 17 medical schools.

Copyright © 1996-2019 The College of Family Physicians of Canada